Review



testing for jak2 various mutations  (Quest Diagnostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Quest Diagnostics testing for jak2 various mutations
    Top, schematic diagram of the <t>JAK2</t> protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.
    Testing For Jak2 Various Mutations, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/testing for jak2 various mutations/product/Quest Diagnostics
    Average 90 stars, based on 1 article reviews
    testing for jak2 various mutations - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms"

    Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0012165

    Top, schematic diagram of the JAK2 protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.
    Figure Legend Snippet: Top, schematic diagram of the JAK2 protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.

    Techniques Used:

    Upper panels: Detection of Δexon14 is relatively easy when the transcript is present at high levels (eg, 29% of total JAK2 transcript). Detection is more difficult when the Δexon14 transcript makes up a small proportion of total JAK2 transcript (eg, 6.9%). Normal control is shown on the bottom.
    Figure Legend Snippet: Upper panels: Detection of Δexon14 is relatively easy when the transcript is present at high levels (eg, 29% of total JAK2 transcript). Detection is more difficult when the Δexon14 transcript makes up a small proportion of total JAK2 transcript (eg, 6.9%). Normal control is shown on the bottom.

    Techniques Used: Control

    Prevalence and Relative Level of the ΔExon14 JAK2 Transcript in Patients with Suspected or Confirmed Myeloproliferative Neoplasms (MPNs)
    Figure Legend Snippet: Prevalence and Relative Level of the ΔExon14 JAK2 Transcript in Patients with Suspected or Confirmed Myeloproliferative Neoplasms (MPNs)

    Techniques Used:

    Lysates were prepared from the indicated human CML K562 cell line (Lane1), a patient with chronic myelogenous leukemia (lane 2), and 5 patients with chronic MPNs (Lanes 3–7). Patient 1: non-CML CMPD, JAK2 V617F positive; Patient 2: non-CML CMPD, JAK2 V617F negative; Patient 3: non-CML CMPD, JAK2 Δexon14 positive; Patient 4: non-CML CMPD, JAK2 Δexon14 positive; Patient 5: non-CML CMPD, JAK2 Δexon14 positive. Top Panel: Probing with an anti-JAK2 N-terminal clone yielded a wild-type JAK2 band at 130 kDa in the K562 and other negative control lanes, and an additional band at 75 kDa only in patients with expression of Δexon14 transcript. Bottom Panel: An anti-JAK2 clone directed against the carboxyl-terminus of JAK2 yielded only a single band at 130 kDa.
    Figure Legend Snippet: Lysates were prepared from the indicated human CML K562 cell line (Lane1), a patient with chronic myelogenous leukemia (lane 2), and 5 patients with chronic MPNs (Lanes 3–7). Patient 1: non-CML CMPD, JAK2 V617F positive; Patient 2: non-CML CMPD, JAK2 V617F negative; Patient 3: non-CML CMPD, JAK2 Δexon14 positive; Patient 4: non-CML CMPD, JAK2 Δexon14 positive; Patient 5: non-CML CMPD, JAK2 Δexon14 positive. Top Panel: Probing with an anti-JAK2 N-terminal clone yielded a wild-type JAK2 band at 130 kDa in the K562 and other negative control lanes, and an additional band at 75 kDa only in patients with expression of Δexon14 transcript. Bottom Panel: An anti-JAK2 clone directed against the carboxyl-terminus of JAK2 yielded only a single band at 130 kDa.

    Techniques Used: Negative Control, Expressing



    Similar Products

    test for the v617f jak2 mutation  (Warnex Inc)
    90
    Warnex Inc test for the v617f jak2 mutation
    Test For The V617f Jak2 Mutation, supplied by Warnex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/test for the v617f jak2 mutation/product/Warnex Inc
    Average 90 stars, based on 1 article reviews
    test for the v617f jak2 mutation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    jak2 mutation testing kits  (Ipsogen Inc)
    90
    Ipsogen Inc jak2 mutation testing kits
    Jak2 Mutation Testing Kits, supplied by Ipsogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jak2 mutation testing kits/product/Ipsogen Inc
    Average 90 stars, based on 1 article reviews
    jak2 mutation testing kits - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    testing for jak2 various mutations  (Quest Diagnostics)
    90
    Quest Diagnostics testing for jak2 various mutations
    Top, schematic diagram of the <t>JAK2</t> protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.
    Testing For Jak2 Various Mutations, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/testing for jak2 various mutations/product/Quest Diagnostics
    Average 90 stars, based on 1 article reviews
    testing for jak2 various mutations - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    jak2 mutation testing  (Quest Diagnostics)
    90
    Quest Diagnostics jak2 mutation testing
    Table 1
    Jak2 Mutation Testing, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jak2 mutation testing/product/Quest Diagnostics
    Average 90 stars, based on 1 article reviews
    jak2 mutation testing - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    plasma testing of jak2 mutations  (Quest Diagnostics)
    90
    Quest Diagnostics plasma testing of jak2 mutations
    Table 1
    Plasma Testing Of Jak2 Mutations, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma testing of jak2 mutations/product/Quest Diagnostics
    Average 90 stars, based on 1 article reviews
    plasma testing of jak2 mutations - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Top, schematic diagram of the JAK2 protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.

    Journal: PLoS ONE

    Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

    doi: 10.1371/journal.pone.0012165

    Figure Lengend Snippet: Top, schematic diagram of the JAK2 protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.

    Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for JAK2 various mutations is offered at Quest Diagnostics.

    Techniques:

    Upper panels: Detection of Δexon14 is relatively easy when the transcript is present at high levels (eg, 29% of total JAK2 transcript). Detection is more difficult when the Δexon14 transcript makes up a small proportion of total JAK2 transcript (eg, 6.9%). Normal control is shown on the bottom.

    Journal: PLoS ONE

    Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

    doi: 10.1371/journal.pone.0012165

    Figure Lengend Snippet: Upper panels: Detection of Δexon14 is relatively easy when the transcript is present at high levels (eg, 29% of total JAK2 transcript). Detection is more difficult when the Δexon14 transcript makes up a small proportion of total JAK2 transcript (eg, 6.9%). Normal control is shown on the bottom.

    Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for JAK2 various mutations is offered at Quest Diagnostics.

    Techniques: Control

    Prevalence and Relative Level of the ΔExon14 JAK2 Transcript in Patients with Suspected or Confirmed Myeloproliferative Neoplasms (MPNs)

    Journal: PLoS ONE

    Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

    doi: 10.1371/journal.pone.0012165

    Figure Lengend Snippet: Prevalence and Relative Level of the ΔExon14 JAK2 Transcript in Patients with Suspected or Confirmed Myeloproliferative Neoplasms (MPNs)

    Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for JAK2 various mutations is offered at Quest Diagnostics.

    Techniques:

    Lysates were prepared from the indicated human CML K562 cell line (Lane1), a patient with chronic myelogenous leukemia (lane 2), and 5 patients with chronic MPNs (Lanes 3–7). Patient 1: non-CML CMPD, JAK2 V617F positive; Patient 2: non-CML CMPD, JAK2 V617F negative; Patient 3: non-CML CMPD, JAK2 Δexon14 positive; Patient 4: non-CML CMPD, JAK2 Δexon14 positive; Patient 5: non-CML CMPD, JAK2 Δexon14 positive. Top Panel: Probing with an anti-JAK2 N-terminal clone yielded a wild-type JAK2 band at 130 kDa in the K562 and other negative control lanes, and an additional band at 75 kDa only in patients with expression of Δexon14 transcript. Bottom Panel: An anti-JAK2 clone directed against the carboxyl-terminus of JAK2 yielded only a single band at 130 kDa.

    Journal: PLoS ONE

    Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

    doi: 10.1371/journal.pone.0012165

    Figure Lengend Snippet: Lysates were prepared from the indicated human CML K562 cell line (Lane1), a patient with chronic myelogenous leukemia (lane 2), and 5 patients with chronic MPNs (Lanes 3–7). Patient 1: non-CML CMPD, JAK2 V617F positive; Patient 2: non-CML CMPD, JAK2 V617F negative; Patient 3: non-CML CMPD, JAK2 Δexon14 positive; Patient 4: non-CML CMPD, JAK2 Δexon14 positive; Patient 5: non-CML CMPD, JAK2 Δexon14 positive. Top Panel: Probing with an anti-JAK2 N-terminal clone yielded a wild-type JAK2 band at 130 kDa in the K562 and other negative control lanes, and an additional band at 75 kDa only in patients with expression of Δexon14 transcript. Bottom Panel: An anti-JAK2 clone directed against the carboxyl-terminus of JAK2 yielded only a single band at 130 kDa.

    Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for JAK2 various mutations is offered at Quest Diagnostics.

    Techniques: Negative Control, Expressing

    Table 1

    Journal: The Journal of Molecular Diagnostics : JMD

    Article Title: Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias

    doi: 10.2353/jmoldx.2009.080114

    Figure Lengend Snippet: Table 1

    Article Snippet: Peripheral blood samples sent to Quest Diagnostics for JAK2 mutation testing were received daily.

    Techniques: